[ad_1]
Following the listing of the first shares of various shares in Hong Kong, the first new company, the non-revenue biotech company, is also preparing to launch its IPO process. According to foreign reports, the songs for the development of drugs for the treatment of hepatitis and liver cancer will begin today roadshows and international investments, with a price per share between 12 and 16 yuan. and $ 343 million to $ 457 million. (a contract of 2.68 billion to 3.56 billion Hong Kong dollars).
In addition, the market is expected to become the Chinese tower of the new capital "king of financing" this year, or delay the IPO and listing, and a new calendar is still outstanding. The stock was initially scheduled to begin offering shares this Friday and will be listed on August 2nd. Recently, the mainland "closed", refused to include companies on the same hand in the list "Hong Kong Stock Connect", and the biotechnology company without income should not get "short-term" The pursuit of Beishui is due to the fact that HSI has already indicated that she had not considered incorporating non-revenue biotech companies into the selection of Hang Seng Composite Index securities.
Guan Yongsheng, director and general manager of HSI, once said that the companies involved are similar to start-up companies, so they need to make other observations and evaluate the company. opportunity to integrate them into Hang Seng KLCI in due course.
The donation ceremony plans to issue 20% of the enlarged share capital If the capitalization limit is 457 million US dollars, its market value after listing will reach 2.285 billion US dollars (about 17.82 billion Hong Kong dollars). The company is tentatively scheduled to open public offers this Friday (20) to next Wednesday (25th) and will be listed on August 1st. It is understood that the songs originally booked 1000 shares per hand, the admission fee is as high as 16161.23 yuan, the subscription group plans to reduce the number of shares by lot last night to reduce the admission fee, but there is no final decision before the deadline. The co-sponsors of the songs are Morgan Stanley, Goldman Sachs and China Merchants Securities International.
The donation was submitted for listing in early May and was the first company to apply for listing on the not-for-profit biotechnology trading system (Chapter 18A) . During the first three months of the year, she realized a turnover of about 51.62 million yuan, but the income came from the advance paid by the company. Roche pharmaceutical company in the licensing agreement of the drug "Gonuowei" instead of Since the sale of drugs.
According to the initial registration document after the hearing of the song, the HCV (hepatitis C virus) treatment drug "Gonuowei" was launched in China on the 27th of the month last and began to be sold nationwide. As Glory markets "Gonuowei" and will continue to develop other drugs, the company expects sales and R & D costs to increase this year, which may affect performance.
Yiju Qilu Lower High Speed Limit Price
The second largest private higher education group in the continent hopes to educate and start pre-routing today, raise funds of $ 400 million million, plans to sell the enlarged share capital% of the shares. Citi and China Merchants Securities International act as co-sponsors.
In addition, the Chinese real estate agent E-House China (02048) will be charged at a lower limit of 14.38 yuan, raising funds of 4.64 billion yuan. Qilu Expressway (01576), a road operator in Shandong Province, will also be charged at the lower limit of the offer price of 2.5 yuan.
[ad_2]
Source link
